Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Current Assets: 2021-2025

Historic Current Assets for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $475.5 million.

  • Kiniksa Pharmaceuticals International's Current Assets rose 52.76% to $475.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $475.5 million, marking a year-over-year increase of 52.76%. This contributed to the annual value of $331.8 million for FY2024, which is 20.09% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Current Assets stood at $475.5 million, which was up 13.14% from $420.3 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Current Assets peaked at $475.5 million during Q3 2025, and registered a low of $179.9 million during Q2 2022.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Current Assets averaged around $316.0 million, with its median value being $301.0 million (2024).
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Current Assets declined by 27.87% in 2022, and later skyrocketed by 52.76% in 2025.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's Current Assets stood at $196.4 million in 2021, then climbed by 23.73% to $243.1 million in 2022, then climbed by 13.67% to $276.3 million in 2023, then rose by 20.09% to $331.8 million in 2024, then surged by 52.76% to $475.5 million in 2025.
  • Its Current Assets was $475.5 million in Q3 2025, compared to $420.3 million in Q2 2025 and $355.9 million in Q1 2025.